Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients with ESLD
NCT ID: NCT06242405
Last Updated: 2025-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
92 participants
INTERVENTIONAL
2024-03-05
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
NCT06167473
Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF
NCT06884904
Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis
NCT01220492
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
NCT03529136
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
NCT05121870
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-infusion group
Single peripheral venous infusion of stem cells
umbilical cord-mesenchymal stem cells
Umbilical cord mesenchymal stem cells injected through peripheral veins
Double-infusion group
Repeated peripheral venous infusion of stem cells within one month
umbilical cord-mesenchymal stem cells
Umbilical cord mesenchymal stem cells injected through peripheral veins
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
umbilical cord-mesenchymal stem cells
Umbilical cord mesenchymal stem cells injected through peripheral veins
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. End-stage liver disease
* 3\. Signed informed consent
Exclusion Criteria
* 2\. Liver transplantation recipients
* 3\. Acute myocardial infarction, acute heart failure, type I and type II respiratory failure, pulmonary embolism, acute cerebral infarction, acute cerebral haemorrhage and other serious cardiopulmonary diseases
* 4\. Other diseases that may seriously affect the survival
* 5\. Human immunodeficiency syndrome
* 6\. Interferon or glucocorticoid therapy within 1 year
* 7\. Treated for mental illness
* 8\. Participation in other clinical trials within 30 days
* 9\. Pregnant or breastfeeding subjects
* 10\. Allergic asthma, allergic urticaria, eczema, or a history of multiple drug and food allergies
* 11\. Other circumstances that are unsuitable for participation in this study
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
General Hospital of Shenyang Military Region
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xingshun Qi
Director of Department of Gastroenterology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xingshun Qi, MD
Role: STUDY_DIRECTOR
The General Hospital of Northern Theater Command
Wen Ning, MM
Role: PRINCIPAL_INVESTIGATOR
The General Hospital of Northern Theater Command
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Hospital of Northern Theater Command
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Volarevic V, Nurkovic J, Arsenijevic N, Stojkovic M. Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells. 2014 Nov;32(11):2818-23. doi: 10.1002/stem.1818.
Wang J, Li Q, Li W, Mendez-Sanchez N, Liu X, Qi X. Stem Cell Therapy for Liver Diseases: Current Perspectives. Front Biosci (Landmark Ed). 2023 Dec 28;28(12):359. doi: 10.31083/j.fbl2812359.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XHNKKY-DFSC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.